A Phase 3 interventional study of MenABCWY and Saline in Meningococcal Vaccine, sponsored by Pfizer. Completed at 78 sites in 5 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of MenABCWY and the comparators in both ACWY-naïve and ACWY-experienced healthy participants ≥10 to \<26 years of age.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACWY Naive subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Naive subjects, Trumenba/MenACWY-CRM
Biological: Trumenba · Biological: MenACWY-CRM
ACWY Experienced subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Experienced subjects, Trumenba/MenACWY-CRM
Biological: Trumenba · Biological: MenACWY-CRM
ACWY Naive subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Naive subjects, Trumenba/MenACWY-CRM
Biological: Trumenba · Biological: MenACWY-CRM
ACWY Experienced subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Experienced subjects, Trumenba/MenACWY-CRM
Biological: Trumenba · Biological: MenACWY-CRM
N meningitidis groups A, B, C, W, and Y vaccine
Placebo
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Bivalent recombinant lipoprotein 2086 vaccine
Meningococcal group A, C, W-135, and Y conjugate vaccine
Percentage of Participants Achieving At Least 4-Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) Titer From Baseline for Each MenACWY Strains: 1 Month After Vaccination 2 in Group 1 Compared to 1 Month After Vaccination 1 in Group 2
4-fold increase was defined as: 1) for participants with baseline hSBA titer below limit of detection (LOD) (or hSBA titer less than \[\<\] 1:4), 4-fold rise was defined as hSBA titer greater than or equal to (\>=) 1:16; 2) baseline hSBA titer \>=LOD and \< lower limit of quantitation (LLOQ) (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided confidence interval (CI) using Clopper and Pearson method was presented. Analysis was performed on post-vaccination (PV) 1 evaluable immunogenicity population (EIP) for Group 2 and PV2 evaluable immunogenicity population for Group 1. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.
Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 1 and 1 month after Vaccination 1 in Group 2
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each of the MenACWY Strains: 1 Month After Vaccination 2 in Group 3 Compared to 1 Month After Vaccination 1 in Group 4
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e., hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.
Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2 in Group 3 and 1 month after Vaccination 1 in Group 4
Percentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined
Percentage of participants achieving hSBA titer \>= LLOQ (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) for all MenB test strains (A22, A56, B24 and B44) combined were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.
Time frame: 1 month after Vaccination 2
Percentage of Participants Achieving At Least a 4-Fold Rise in hSBA Titer From Baseline For Each Primary MenB Test Strains at 1 Month After Vaccination 2: Groups 1 and 3 Combined Versus Groups 2 and 4 Combined
Percentage of participants achieving at least a 4-fold rise in hSBA titer for each primary MenB test strains (A22, A56, B24 and B44) were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.
Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 2
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius (C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
The use of antipyretic medication was recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
The use of antipyretic medication recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Within 30 days after Vaccination 1
Percentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Within 30 days after Vaccination 2
Percentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Within 30 days after any vaccination
Percentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 1
Percentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 2
Percentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after any vaccination
Percentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Percentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Percentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 1
Percentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 2
Percentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after any vaccination
Percentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Percentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Percentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 1
Percentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 days after Vaccination 2
Percentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 Days after any vaccination
Percentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Percentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From 1 month after Vaccination 2 up to 6 months after Vaccination 2 (approximately 5 months)
Percentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: From day of Vaccination 1 (Day 1) up to 6 months after Vaccination 2 (approximately 12 months)
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 minutes after Vaccination 1
Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.
Time frame: Within 30 minutes after Vaccination 2
Percentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Percentage of participants who missed days of school or work due to AEs during vaccination phase were reported in this outcome measure.
Time frame: From day of Vaccination 1 (Day 1) up to 1 month after Vaccination 2 (approximately 7 months)
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 1 Compared to Group 2
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.
Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1
Percentage of Participants Achieving At Least 4-Fold Rise in hSBA Titer From Baseline for Each MenACWY Test Strains: 1 Month After Vaccination 1 in Group 3 Compared to Group 4
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \> =LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.
Time frame: Baseline (pre-vaccination on Day 1), 1 month after Vaccination 1
| Milestone | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) |
|---|---|---|---|---|---|---|---|---|
| Started | 552 | 276 | 528 | 261 | 544 | 57 | 154 | 59 |
| Vaccination 1 | 547 | 274 | 526 | 261 | 537 | 56 | 153 | 59 |
| Vaccination 2 | 500 | 254 | 453 | 218 | 481 | 46 | 123 | 45 |
| Completed | 490 | 248 | 440 | 209 | 476 | 45 | 122 | 44 |
| Not completed | 62 | 28 | 88 | 52 | 68 | 12 | 32 | 15 |
| Withdrew: Lost to follow-up | 26 | 15 | 42 | 22 | 30 | 3 | 18 | 5 |
| Withdrew: Medication error without associated adverse event | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 5 | 1 | 5 | 2 | 3 | 0 | 2 | 3 |
| Withdrew: Pregnancy | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 5 | 3 | 0 | 0 | 3 | 0 |
| Withdrew: Other | 0 | 0 | 3 | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 11 | 5 | 18 | 14 | 10 | 3 | 5 | 4 |
| Withdrew: Withdrawal by parent/guardian | 10 | 4 | 11 | 7 | 16 | 4 | 3 | 2 |
| Withdrew: Withdrawn before vaccination | 5 | 2 | 2 | 0 | 7 | 1 | 1 | 0 |
| Milestone | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) |
|---|---|---|---|---|---|---|---|---|
| Started | 490 | 248 | 440 | 209 | 476 | 45 | 122 | 44 |
| Completed | 487 | 243 | 440 | 208 | 475 | 45 | 120 | 43 |
| Not completed | 3 | 5 | 0 | 1 | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 | 0 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
4-fold increase was defined as: 1) for participants with baseline hSBA titer below limit of detection (LOD) (or hSBA titer less than \[\<\] 1:4), 4-fold rise was defined as hSBA titer greater than or equal to (\>=) 1:16; 2) baseline hSBA titer \>=LOD and \< lower limit of quantitation (LLOQ) (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided confidence interval (CI) using Clopper and Pearson method was presented. Analysis was performed on post-vaccination (PV) 1 evaluable immunogenicity population (EIP) for Group 2 and PV2 evaluable immunogenicity population for Group 1. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.
| Percentage of participants | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) |
|---|---|---|
| MenA | 97.8 (95.9 to 98.9) | 95.3 (91.9 to 97.5) |
| MenC | 93.3 (90.6 to 95.5) | 52.4 (46.0 to 58.7) |
| MenW | 97.3 (95.3 to 98.6) | 73.0 (66.9 to 78.4) |
| MenY | 94.4 (91.8 to 96.3) | 70.6 (64.5 to 76.2) |
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e., hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented. Here, 'Overall Number of Participants Analyzed' represented as 'N' and 'Number Analyzed' represented as 'n'.
| Percentage of participants | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) |
|---|---|---|
| MenA | 93.8 (90.9 to 96.0) | 96.9 (93.7 to 98.8) |
| MenC | 93.8 (90.9 to 96.0) | 94.7 (90.9 to 97.2) |
| MenW | 97.1 (94.8 to 98.5) | 96.4 (93.0 to 98.4) |
| MenY | 93.0 (90.0 to 95.4) | 93.7 (89.7 to 96.5) |
Percentage of participants achieving hSBA titer \>= LLOQ (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) for all MenB test strains (A22, A56, B24 and B44) combined were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.
| Percentage of participants | Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) | Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) |
|---|---|---|
| Percentage of Participants Achieving hSBA Titer Greater Than or Equal to (>=) LLOQ for All Primary Neisseria Meningitidis Group B (MenB) Test Strains Combined (Composite Response): Groups 1 and 3 Combined Versus Groups 2 and 4 Combined | 78.3 (75.2 to 81.2) | 68.7 (63.8 to 73.3) |
Percentage of participants achieving at least a 4-fold rise in hSBA titer for each primary MenB test strains (A22, A56, B24 and B44) were reported in this outcome measure. Exact 2-sided CI using the Clopper and Pearson method was presented.
| Percentage of participants | Groups 1+3 Combined MenABCWY + Saline (Immunogenicity and Safety Set) | Groups 2+4 Combined Trumenba + MenACWY-CRM (Immunogenicity and Safety Set) |
|---|---|---|
| A22 | 83.0 (80.2 to 85.6) | 79.0 (74.7 to 82.9) |
| A56 | 95.9 (94.3 to 97.2) | 94.5 (91.8 to 96.5) |
| B24 | 68.1 (64.8 to 71.2) | 57.2 (52.3 to 62.0) |
| B44 | 86.5 (84.0 to 88.7) | 79.2 (75.0 to 83.0) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 centimeter (cm) and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Redness: Mild | 8.8 (7.5 to 10.3) | 7.3 (5.4 to 9.6) |
| Redness: Moderate | 14.5 (12.8 to 16.2) | 10.0 (7.8 to 12.6) |
| Redness: Severe | 2.5 (1.8 to 3.3) | 2.2 (1.2 to 3.7) |
| Swelling: Mild | 10.5 (9.0 to 12.0) | 8.3 (6.2 to 10.7) |
| Swelling: Moderate | 13.3 (11.7 to 15.0) | 12.4 (9.9 to 15.2) |
| Swelling: Severe | 1.2 (0.7 to 1.8) | 0.8 (0.3 to 1.8) |
| Pain at injection site: Mild | 32.3 (30.1 to 34.6) | 31.1 (27.5 to 34.9) |
| Pain at injection site: Moderate | 49.5 (47.1 to 51.9) | 47.6 (43.7 to 51.6) |
| Pain at injection site: Severe | 7.5 (6.3 to 8.8) | 6.3 (4.6 to 8.5) |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an e-diary. Redness and swelling were measured and recorded in caliper units. 1 caliper unit =0.5 cm and graded as mild: \>2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at injection site were reported in this outcome measure. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Redness: Mild | 7.7 (6.4 to 9.2) | 6.6 (4.7 to 9.1) |
| Redness: Moderate | 12.6 (10.9 to 14.4) | 7.2 (5.1 to 9.7) |
| Redness: Severe | 3.0 (2.1 to 4.0) | 0.9 (0.3 to 2.2) |
| Swelling: Mild | 10.4 (8.9 to 12.1) | 6.4 (4.5 to 8.9) |
| Swelling: Moderate | 12.8 (11.1 to 14.6) | 8.1 (5.9 to 10.8) |
| Swelling: Severe | 1.0 (0.5 to 1.6) | 0.2 (0.0 to 1.0) |
| Pain at injection site: Mild | 29.1 (26.7 to 31.5) | 33.1 (29.1 to 37.3) |
| Pain at injection site: Moderate | 48.8 (46.2 to 51.4) | 40.3 (36.1 to 44.6) |
| Pain at injection site: Severe | 6.5 (5.3 to 7.9) | 5.3 (3.5 to 7.6) |
Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 degrees (deg) Celsius (C) and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Fever: 38.0 deg C to 38.4 deg C | 3.7 (2.8 to 4.7) | 2.0 (1.1 to 3.5) |
| Fever: >38.4 deg C to 38.9 deg C | 1.6 (1.0 to 2.3) | 2.8 (1.7 to 4.4) |
| Fever: >38.9 deg C to 40.0 deg C | 0.6 (0.3 to 1.1) | 0.9 (0.3 to 2.0) |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.6) |
| Fatigue: Mild | 23.5 (21.5 to 25.5) | 25.7 (22.4 to 29.3) |
| Fatigue: Moderate | 25.5 (23.4 to 27.6) | 25.7 (22.4 to 29.3) |
| Fatigue: Severe | 3.2 (2.4 to 4.1) | 3.3 (2.0 to 5.0) |
| Headache: Mild | 25.6 (23.6 to 27.8) | 24.5 (21.2 to 28.0) |
| Headache: Moderate | 19.2 (17.4 to 21.1) | 20.4 (17.3 to 23.7) |
| Headache: Severe | 1.9 (1.3 to 2.7) | 2.0 (1.1 to 3.5) |
| Chills: Mild | 12.6 (11.1 to 14.2) | 10.2 (8.0 to 12.8) |
| Chills: Moderate | 6.7 (5.5 to 7.9) | 7.8 (5.9 to 10.2) |
| Chills: Severe | 0.8 (0.4 to 1.3) | 1.6 (0.8 to 2.9) |
| Vomiting: Mild | 2.5 (1.8 to 3.4) | 2.0 (1.1 to 3.5) |
| Vomiting: Moderate | 0.6 (0.3 to 1.1) | 0.9 (0.3 to 2.0) |
| Vomiting: Severe | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.6) |
| Diarrhea: Mild | 8.7 (7.5 to 10.2) | 11.9 (9.5 to 14.7) |
| Diarrhea: Moderate | 2.0 (1.4 to 2.7) | 1.6 (0.8 to 2.9) |
| Diarrhea: Severe | 0.3 (0.1 to 0.7) | 0.0 (0.0 to 0.6) |
| Muscle Pain: Mild | 13.6 (12.0 to 15.3) | 13.5 (10.9 to 16.4) |
| Muscle Pain: Moderate | 10.5 (9.1 to 12.1) | 11.9 (9.5 to 14.7) |
| Muscle Pain: Severe | 1.6 (1.1 to 2.3) | 2.0 (1.1 to 3.5) |
| Joint Pain: Mild | 10.7 (9.3 to 12.2) | 12.9 (10.4 to 15.7) |
| Joint Pain: Moderate | 8.6 (7.3 to 10.0) | 8.6 (6.6 to 11.1) |
| Joint Pain: Severe | 1.0 (0.6 to 1.6) | 1.1 (0.4 to 2.2) |
Systemic events were recorded by participants in e-diary. Fever was defined as temperature \>=38.0 deg C and was categorized as 38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24h, moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Fever: 38.0 deg C to 38.4 deg C | 1.8 (1.2 to 2.6) | 0.4 (0.0 to 1.4) |
| Fever: >38.4 deg C to 38.9 deg C | 0.3 (0.1 to 0.7) | 0.9 (0.3 to 2.2) |
| Fever: >38.9 deg C to 40.0 deg C | 0.2 (0.0 to 0.6) | 0.2 (0.0 to 1.0) |
| Fever: >40.0 deg C | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.7) |
| Fatigue: Mild | 22.8 (20.7 to 25.1) | 22.0 (18.5 to 25.8) |
| Fatigue: Moderate | 21.8 (19.7 to 24.0) | 19.9 (16.6 to 23.6) |
| Fatigue: Severe | 2.9 (2.1 to 3.9) | 1.7 (0.8 to 3.2) |
| Headache: Mild | 21.3 (19.2 to 23.5) | 21.1 (17.7 to 24.8) |
| Headache: Moderate | 16.8 (14.9 to 18.8) | 16.2 (13.1 to 19.6) |
| Headache: Severe | 1.7 (1.1 to 2.5) | 0.6 (0.1 to 1.6) |
| Chills: Mild | 9.9 (8.5 to 11.6) | 8.8 (6.6 to 11.6) |
| Chills: Moderate | 6.0 (4.9 to 7.4) | 5.8 (4.0 to 8.2) |
| Chills: Severe | 0.4 (0.2 to 0.9) | 1.5 (0.7 to 2.9) |
| Vomiting: Mild | 1.4 (0.8 to 2.1) | 0.8 (0.2 to 1.9) |
| Vomiting: Moderate | 0.1 (0.0 to 0.5) | 0.2 (0.0 to 1.0) |
| Vomiting: Severe | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.7) |
| Diarrhea: Mild | 6.9 (5.6 to 8.3) | 6.0 (4.2 to 8.4) |
| Diarrhea: Moderate | 1.4 (0.8 to 2.1) | 2.4 (1.3 to 4.1) |
| Diarrhea: Severe | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.7) |
| Muscle Pain: Mild | 10.0 (8.5 to 11.7) | 10.0 (7.6 to 12.8) |
| Muscle Pain: Moderate | 11.9 (10.3 to 13.7) | 11.5 (8.9 to 14.5) |
| Muscle Pain: Severe | 0.8 (0.4 to 1.4) | 0.8 (0.2 to 1.9) |
| Joint Pain: Mild | 9.6 (8.1 to 11.2) | 7.9 (5.7 to 10.5) |
| Joint Pain: Moderate | 8.3 (6.9 to 9.8) | 6.8 (4.8 to 9.2) |
| Joint Pain: Severe | 0.4 (0.2 to 0.9) | 0.9 (0.3 to 2.2) |
The use of antipyretic medication was recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 29.5 (27.4 to 31.7) | 28.1 (24.6 to 31.7) |
The use of antipyretic medication recorded by participants in an e-diary for 7 days after vaccination. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Use of Antipyretic Medication Within 7 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 25.1 (22.9 to 27.4) | 20.5 (17.1 to 24.2) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 5.8 (4.7 to 7.0) | 6.5 (4.7 to 8.6) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With AEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 5.3 (4.3 to 6.6) | 3.7 (2.3 to 5.7) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With AEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 9.7 (8.4 to 11.2) | 9.1 (7.0 to 11.6) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Exact 2-sided CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 20.9 (19.0 to 22.8) | 20.3 (17.3 to 23.6) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.06 (0.0 to 0.3) | 0.0 (0.0 to 0.6) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With SAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.1 (0.0 to 0.5) | 0.0 (0.0 to 0.7) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With SAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.2 (0.0 to 0.5) | 0.0 (0.0 to 0.6) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With SAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.4 (0.2 to 0.8) | 0.0 (0.0 to 0.6) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With SAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.3 (0.1 to 0.7) | 0.8 (0.2 to 2.0) |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent disability/ incapacity; congenital anomaly/birth defect and other important medical events. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With SAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.6 (0.3 to 1.1) | 0.6 (0.2 to 1.6) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 3.6 (2.8 to 4.5) | 4.3 (2.9 to 6.2) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With MAEs Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 3.6 (2.7 to 4.6) | 2.8 (1.6 to 4.6) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With MAEs Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 6.3 (5.2 to 7.5) | 6.3 (4.6 to 8.5) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With MAEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 14.9 (13.3 to 16.7) | 14.3 (11.7 to 17.3) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With MAEs During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 9.3 (7.8 to 10.9) | 7.5 (5.3 to 10.1) |
MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With MAEs Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 19.3 (17.5 to 21.2) | 18.3 (15.4 to 21.5) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.2 (0.1 to 0.6) | 0.0 (0.0 to 0.6) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With NDCMC Within 30 Days After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.06 (0.0 to 0.4) | 0.0 (0.0 to 0.7) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With NDCMC Within 30 Days After Any Vaccination: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.3 (0.1 to 0.7) | 0.0 (0.0 to 0.6) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With NDCMC During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 1.1 (0.7 to 1.7) | 0.3 (0.0 to 1.1) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With NDCMC During Follow-up Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0.4 (0.1 to 0.8) | 0.0 (0.0 to 0.7) |
An NDCMC was defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With NDCMC Throughout the Study: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 1.4 (0.9 to 2.1) | 0.3 (0.0 to 1.1) |
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 1: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0 (NA to NA) | 0 (NA to NA) |
Immediate AEs were defined as AEs occurring within the first 30 minutes after investigational product administration. Exact 2-sided CI was based on the Clopper and Pearson method.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants With Immediate AE Within 30 Minutes After Vaccination 2: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 0 (NA to NA) | 0 (NA to NA) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of investigational product, whether or not considered related to the investigational product. Percentage of participants who missed days of school or work due to AEs during vaccination phase were reported in this outcome measure.
| Percentage of participants | Groups 1+3+5+7 Combined MenABCWY + Saline | Groups 2+4+6+8 Combined Trumenba + MenACWY-CRM |
|---|---|---|
| Percentage of Participants Who Missed Days of School or Work Due to AEs During Vaccination Phase: By MenABCWY Group (Groups 1, 3, 5, and 7 Combined) and Trumenba Group (Groups 2, 4, 6, and 8 Combined) | 5.0 | 4.5 |
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4times LLOQ; 3) baseline hSBA titer \>=LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.
| Percentage of participants | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) |
|---|---|---|
| MenA | 97.0 (95.1 to 98.3) | 95.3 (91.9 to 97.5) |
| MenC | 62.9 (58.5 to 67.1) | 52.4 (46.0 to 58.7) |
| MenW | 79.3 (75.4 to 82.8) | 73.0 (66.9 to 78.4) |
| MenY | 82.0 (78.3 to 85.3) | 70.6 (64.5 to 76.2) |
4-fold increase was defined as: 1) for participants with baseline hSBA titer below LOD (or hSBA titer \<1:4), 4-fold rise was defined as hSBA titer \>=1:16; 2) baseline hSBA titer \>=LOD (i.e., hSBA titer of \>=1:4) and \< LLOQ (i.e. hSBA titer of 1:8), 4-fold rise was defined as hSBA titer \>=4 times LLOQ; 3) baseline hSBA titer \> =LLOQ, 4-fold rise was defined as hSBA titer \>=4 times baseline titer. Exact 2-sided CI using Clopper and Pearson method was presented.
| Percentage of participants | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) |
|---|---|---|
| MenA | 94.8 (92.2 to 96.7) | 96.9 (93.7 to 98.8) |
| MenC | 93.4 (90.7 to 95.5) | 94.7 (90.9 to 97.2) |
| MenW | 97.4 (95.4 to 98.7) | 96.4 (93.0 to 98.4) |
| MenY | 94.3 (91.8 to 96.3) | 93.7 (89.7 to 96.5) |
Collected over Local reactions and systemic events recorded using systematic assessment within 7 days after Vaccination 1 and 2; SAEs and all-cause mortality recorded using non-systematic assessment from Day 1 up to 6 months after vaccination 2 (approximately 12 months) and other AEs recorded using non-systematic assessment from Day 1 up to 1 month after vaccination 2 (approximately 7 months). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | 0/547 (0%) | 6/547 (1.1%) | 533/547 (97.4%) |
| ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | 0/274 (0%) | 1/274 (0.4%) | 262/274 (95.6%) |
| ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | 0/526 (0%) | 3/526 (0.6%) | 504/526 (95.8%) |
| ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | 0/260 (0%) | 2/260 (0.8%) | 244/260 (93.8%) |
| ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | 0/537 (0%) | 2/537 (0.4%) | 512/537 (95.3%) |
| ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | 0/56 (0%) | 1/56 (1.8%) | 53/56 (94.6%) |
| ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | 0/153 (0%) | 0/153 (0%) | 148/153 (96.7%) |
| ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) | 0/59 (0%) | 0/59 (0%) | 58/59 (98.3%) |
| Event | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) |
|---|---|---|---|---|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/547 | 0/274 | 0/526 | 0/260 | 0/537 | 1/56 | 0/153 | 0/59 |
| Escherichia urinary tract infectionInfections and infestations | 0/547 | 0/274 | 0/526 | 1/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Status migrainosusNervous system disorders | 0/547 | 0/274 | 0/526 | 1/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| DepressionPsychiatric disorders | 2/547 | 0/274 | 0/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| AppendicitisInfections and infestations | 0/547 | 1/274 | 0/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Gastroenteritis salmonellaInfections and infestations | 0/547 | 0/274 | 1/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/547 | 0/274 | 1/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Food intoleranceMetabolism and nutrition disorders | 0/547 | 0/274 | 1/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Depression suicidalPsychiatric disorders | 0/547 | 0/274 | 1/526 | 0/260 | 0/537 | 0/56 | 0/153 | 0/59 |
| Spinal cord injuryInjury, poisoning and procedural complications | 0/547 | 0/274 | 0/526 | 0/260 | 1/537 | 0/56 | 0/153 | 0/59 |
| Event | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) |
|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 522/547 | 247/274 | 486/526 | 228/260 | 493/537 | 51/56 | 144/153 | 57/59 |
| Fatigue (FATIGUE)General disorders | 364/547 | 183/274 | 337/526 | 160/260 | 317/537 | 30/56 | 99/153 | 43/59 |
| Headache (HEADACHE)Nervous system disorders | 330/547 | 152/274 | 312/526 | 161/260 | 282/537 | 24/56 | 86/153 | 37/59 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 198/547 | 97/274 | 207/526 | 97/260 | 167/537 | 18/56 | 57/153 | 22/59 |
| Swelling (SWELLING)General disorders | 186/547 | 71/274 | 158/526 | 57/260 | 200/537 | 16/56 | 49/153 | 19/59 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 183/547 | 75/274 | 162/526 | 58/260 | 190/537 | 15/56 | 39/153 | 16/59 |
| Chills (CHILLS)General disorders | 155/547 | 78/274 | 151/526 | 59/260 | 130/537 | 14/56 | 43/153 | 19/59 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 156/547 | 75/274 | 156/526 | 83/260 | 144/537 | 12/56 | 48/153 | 19/59 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 69/547 | 50/274 | 116/526 | 54/260 | 72/537 | 8/56 | 23/153 | 8/59 |
| Pyrexia (FEVER)General disorders | 44/547 | 24/274 | 29/526 | 13/260 | 42/537 | 3/56 | 8/153 | 3/59 |
Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination. One participant initially randomized to group 3 was excluded from safety population set as the participant received the wrong vaccination (Trumenba + saline).
| Age, Continuous(Years) | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 16.7 ± 5.49 | 16.7 ± 5.39 | 17.3 ± 3.17 | 17.4 ± 3.28 | 13.5 ± 4.05 | 13.5 ± 4.50 | 17.1 ± 3.04 | 16.0 ± 2.75 | 16.1 ± 4.55 |
| Sex: Female, Male(Participants) | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 289 | 140 | 279 | 131 | 253 | 20 | 96 | 28 | 1236 |
| Male | 258 | 134 | 247 | 129 | 284 | 36 | 57 | 31 | 1176 |
| Ethnicity (NIH/OMB)(Participants) | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 93 | 53 | 156 | 86 | 131 | 15 | 58 | 29 | 621 |
| Not Hispanic or Latino | 450 | 217 | 366 | 173 | 405 | 41 | 93 | 30 | 1775 |
| Unknown or Not Reported | 4 | 4 | 4 | 1 | 1 | 0 | 2 | 0 | 16 |
| Race (NIH/OMB)(Participants) | ACWY-Naive: Group 1 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Naive: Group 2 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Experienced: Group 3 MenABCWY + Saline (Immunogenicity and Safety Set) | ACWY-Experienced: Group 4 Trumenba+ MenACWY - CRM (Immunogenicity and Safety Set) | ACWY-Naive: Group 5 MenABCWY + Saline (Safety Set) | ACWY-Naive: Group 6 Trumenba+ MenACWY - CRM (Safety Set) | ACWY-Experienced: Group 7 MenABCWY + Saline (Safety Set) | ACWY-Experienced: Group 8 Trumenba+ MenACWY - CRM (Safety Set) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 2 | 2 | 4 | 1 | 2 | 1 | 16 |
| Asian | 19 | 4 | 18 | 6 | 7 | 1 | 1 | 1 | 57 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 4 |
| Black or African American | 26 | 19 | 74 | 32 | 57 | 5 | 27 | 5 | 245 |
| White | 467 | 239 | 370 | 195 | 419 | 46 | 103 | 42 | 1881 |
| More than one race | 9 | 3 | 12 | 3 | 7 | 2 | 2 | 0 | 38 |
| Unknown or Not Reported | 23 | 7 | 48 | 22 | 42 | 1 | 18 | 10 | 171 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2020 to primary completion in Jul 2022, 25 months.
Results were first posted in Apr 2023, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meningococcal pentavalent vaccine · MenB-FHbp vaccine · 4CMenB vaccine